Concord Biotech Limited has intimated the stock exchanges about an upcoming meeting of its Board of Directors scheduled for Friday, July 31, 2026. The primary agenda of the board meeting is to consider and approve the unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. The financial results will be accompanied by a Limited Review Report issued by the company's Statutory Auditors.
The company also confirmed the continuation of the trading window closure that was previously communicated via letter dated June 27, 2026. The trading window for dealing in the company's securities will remain closed until 48 hours after the declaration of the financial results for Q1 FY2027. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal Code of Conduct to Regulate, Monitor and Report trading by Designated Persons and their immediate relatives.
The disclosure is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed entities to intimate stock exchanges about board meetings where financial results will be considered.
The communication was digitally signed by Paritosh Trivedi, Company Secretary and Compliance Officer (ACS 63623), on July 28, 2026 at 19:00:03 IST.